尊龙凯时人生就是搏·(中国区)官方网站

VOLUNTARY ANNOUNCEMENT

AMENDED AND RESTATED ARTICLES OF ASSOCIATION

VOLUNTARY ANNOUNCEMENT - TQC3721 INHALATION SUSPENSION "PDE3/4 INHIBITOR" OBTAINING APPROVAL FOR PHASE III REGISTRATIONAL CLINICAL STUDY FROM CDE

VOLUNTARY ANNOUNCEMENT - DATA FROM PHASE III STUDY OF BENMELSTOBART WITH OR WITHOUT ANLOTINIB AS MAINTENANCE TREATMENT FOR NON-SMALL CELL LUNG CANCER WITHOUT PROGRESSION FOLLOWING CHEMORADIOTHERAPY PRESENTED AT 2025 ASCO ANNUAL MEETING

VOLUNTARY ANNOUNCEMENT - DATA FROM PHASE III STUDY OF BENMELSTOBART IN COMBINATION WITH ANLOTINIB AS FIRST-LINE TREATMENT FOR PD-L1 POSITIVE NON-SMALL CELL LUNG CANCER PRESENTED AT 2025 ASCO ANNUAL MEETING

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MAY 2025

VOLUNTARY ANNOUNCEMENT

VOLUNTARY ANNOUNCEMENT - DATA FROM PHASE I STUDY OF TQB2102 (BISPECIFIC ANTI-HER2 ADC) PRESENTED AT 2025 ASCO ANNUAL MEETING